Post-Introduction Evaluation (PIE) of Covid-19 Vaccination in Delhi: Application of WHO Framework
DOI:
https://doi.org/10.56450/JEFI.2025.v3i01.011Keywords:
Adverse Effect Following Immunization, Covid-19, Cold Chain Points, Cold Chain Handlers, Health Facilities, cPIE, Vaccine HesitancyAbstract
The present study was undertaken for the Post-Introduction Evaluation (PIE) of COVID-19 vaccination across different levels of healthcare system in Delhi. It was conducted in accordance with the guideline provided in the WHO PIE tool to assess the COVID-19 vaccine introduction and document strength and weaknesses. The study found that The detailed operational plans were available at state, district and health facility levels. Both electronic and paper-based reporting and recording mechanism were deployed for COVID-19 vaccination. There was neither stock out nor expiry reported for COVID-19 vaccine. There was an AEFI committee functional with availability of a system and written protocol for monitoring and reporting of AEFIs of COVID-19 vaccine
Downloads
References
1. World Health Organization. New Vaccine Post-Introduction Evaluation (PIE) Tool. Geneva: World Health Organization:2010. https://iris.who.int/bitstream/handle/10665/70436/WHO_IVB_10.03_eng.pdf (Accessed on 25-03-2025)
2. World Health Organization. COVID-19 vaccine post-introduction evaluation (cPIE). Geneva, Switzerland: World Health Organization; 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-cPIE-2021.1 (Accessed on 25-03-2025)
3. Ministry of Health and Family Welfare, Government of India. COVID-19 Vaccination India begins World’s Largest Vaccination Drive on 16 January [Internet]. 2021. Available from: https://www.pib.gov.in/PressReleasePage.aspx?PRID=1689112 (Accessed on 25-03-2025)
4. Government of India. Revised Guidelines for implementation of National COVID Vaccination Program. New Delhi: Ministry of Health and Family Welfare, Government of India; 2021. Available from: https://covid19.india.gov.in/document/revised-guidelines-for-implementation-of-national-covid-vaccination-program/ (Accessed on 25-03-2025)
5. Government of India. COVID-19 Vaccines, Operational Guidelines December 2020. New Delhi: Ministry of Health and Family Welfare, Government of India. 2020. https://covid19dashboard.mohfw.gov.in/pdf/COVID19VaccineOG111Chapter16.pdf (Accessed on 25-03-2025)
6. Lahariya C, Paruthi R, Bhattacharya M. How a New Health Intervention Affects the Health Systems? Learnings from Pentavalent Vaccine Introduction in India. The Indian Journal of Pediatrics. 2015;83(4):294-299. DOI: https://doi.org/10.1007/s12098-015-1844-x
7. Ahmed D, VanderEnde K, Harvey P, et al. Human papillomavirus (HPV) vaccine introduction in Sikkim state: Best practices from the first statewide multiple-age cohort HPV vaccine introduction in India-2018-2019. Vaccine. 2022;40 Suppl 1(Suppl 1):A17-A25. DOI: https://doi.org/10.1016/j.vaccine.2021.07.024
8. Chowdhury AK, Roy T, Faroque AB, Bachar SC, Asaduzzaman M, Nasrin N. et al. A comprehensive situation assessment of injection practices in primary health care hospitals in Bangladesh. BMC Public Health. 2011 Oct 10;11:779. DOI: https://doi.org/10.1186/1471-2458-11-779
9. Joshi J, Das MK, Polpakara D, Aneja S, Agarwal M, Arora NK. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India. Indian J Pediatr. 2018;85(2):139-148. DOI: https://doi.org/10.1007/s12098-017-2532-9
10. Mittal S, Rawat C, Gupta A, Solanki HK, Singh RK. Adverse Events Following Immunization Among Children Under Two Years of Age: A Prospective Observational Study From North India. Cureus. 2023;15(4):e38356. DOI: https://doi.org/10.7759/cureus.38356
11. National Institute of Epidemiology, Indian Council of Medical Research. Report of Programme Implementation Review following Rotavirus vaccine introduction in India - A Rapid assessment. Chennai, India: National Institute of Epidemiology, Indian Council of Medical Research; 2016. Available from: http://www.icmr.nic.in . (Accessed on 25-03-2025)
12. World Health Organization. Report of the post introduction evaluation of Haemophilus influenza type b (Hib) as pentavalent (DPT + HepB + _Hib) vaccine in Tamil Nadu and Kerala, India, 2012. New Delhi: World Health Organization Country Office for India; 2012.
13. Malik A, Haldar P, Ray A, Shet A, Kapuria B, Bhadana S. et al. Introducing rotavirus vaccine in the Universal Immunization Programme in India: From evidence to policy to implementation. Vaccine. 2019 Sep 16;37(39):5817-5824. DOI: https://doi.org/10.1016/j.vaccine.2019.07.104
14. World Health Organization. Post-Introduction Evaluation (PIE) of Pentavalent (DTP-Hib-Hepatitis B) and Inactivated Polio Vaccines. New Delhi: World Health Organization, Regional office for South East Asia; 2017 https://iris.who.int/bitstream/handle/10665/272402/sea-immun-111.pdf?sequence=1&isAllowed=y (Accessed on 25-03-2025)
15. Lahariya C, Subramanya B P, Sosler S. An assessment of hepatitis B vaccine introduction in India: Lessons for roll out and scale up of new vaccines in immunization programs. Indian Journal of Public Health 2013;57(1):8-14 DOI: https://doi.org/10.4103/0019-557X.111357
16. World Health Organization. Post-Introduction Evaluation of Pentavalent Vaccine and Measles-containing Vaccine Second dose in Goa, Gujarat, Haryana, Jammu and Kashmir, Karnataka and Puducherry. New Delhi: World Health Organization, Country Office for India; 2014.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ngangom Kanchan, Vijay Kumar Tiwari, Sherin Raj TP (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
